Symposium etc.

Update: 08/06/13

Symposium

Symposium 1 (S1)

[The bench-to-bedside researches for renal drug transporters and channels]

	Organizer：
	Hideyuki Saito	(Department of Pharmacy, Kumamoto University Hospital)
	Mikihisa Takano	(Department of Pharmaceutics and Therapeutics, Graduate School of Biomedical Sciences, Hiroshima University)

【Plenary Lecture】
New progress in transporter and channel research
   Sei Sasaki
(Department of Nephrology, Tokyo Medical and Dental University)

1. Proximal tubule-specific transporter manipulation in transgenic animals
      Takaaki Abe
   (Division of Nephrology, Endocrinology, and Vascular Medicine, Department of Medicine, Tohoku University Graduate School of Medicine）
2. Renal urate transpoters and serum urate disorder
      Naohiko Anzai1), Hitoshi Endou1,2)
   (1)Department of Pharmacology and Toxicology, Kyorin University School of Medicine, 2) J-Pharma Co. Ltd）
3. Mchanisms of tubular secretion of drugs in the kidney, and drug interactions involving drug transporters
      Hiroyuki Kusuhara
   (Graduate School of Pharmaceutical Sciences, The University of Tokyo)
4. Pathophysiological roles of renal drug transpoters
      Satohiro Masuda, Ken-ichi Inui
   (Department of Pharmacy, Kyoto University Hospital)

Symposium 2 (S2)

[Recent progress in regulation mechanisms of drug metabolizing enzymes and transporters]

	Organizer:
	Tomohiro Terada	(Department of Pharmacy, Kyoto University Hospital)
	Tsuyoshi Yokoi	(Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)

OVERVIEW
Tsuyoshi Yokoi
(Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)

1. Bile acid, lipid and fxr control
      Masaaki Miyata, Yuki Takamatsu, Masahiro Nomoto, Yasushi Yamazoe
   (Division of Drug Metabolism and Molecular Toxicology, Graduate School of Pharmaceutical Sciences, Tohoku University)
2. Differentiation of human embryonic stem cells into hepatocytes and pharmacokinetic studies
      Tamihide Matsunaga, Shigeru Ohmori
   (Department of Pharmacy, Shinshu University Hospital)
3. Regulation of drug metabolizing enzymes and nuclear receptors by micrornas
      Miki Nakajima, Shingo Takagi, Sayaka Komagata, Takuya Mohri, Yuki Tsuchiya, and Tsuyoshi Yokoi.
   (Drug Metabolism and Taxicology, Graduate School of Medical Sciences,Kanazawa University)
4. Molecular clock mechanisms of drug pharmacokinetics
      Naoya Matsunaga, Satoru Koyanagi, Shigehiro Ohdo
   (Pharmaceutics, Faculty of Pharmaceutical Sciences, Kyushu University)
5. Gene regulation of drug transpoters
      Tomohiro Terada, Ken-ichi Inui
   (Department of Pharmacy, Kyoto University Hospital)

Symposium 3 (S3)

“International symposium on development of albumins with new functions and clinical applications”
Organizer:
   Masaki Otagiri (Japan)
   U. Kragh-Hansen (Denmark)

【Welcoming Speech】 Masaki Otagiri (Japan)

Section 1: Current approaches in protein binding studies

1. Crystallographic analysis of small molecule binding to HSA: what have we learned?
      Stephen Curry (United Kingdom)
2. Site-directed mutagenesis study of key amino acids in the ligand binding domains of human serum albumin
      Chung-Eun Ha (USA)
3. Identification of drug binding site on plasma proteins using photoaffinity labelling technique
      Victor Tuan Giam Chuang (Australia)

Section 2: Biological activities for new therapeutic opportunities

1. Role of albumin in amyloidosis: a novel therapeutic target in amyloid formation
      Yukio Ando (Japan)
2. The MHC class I-related FcRn protects albumin and IgG from degradation: implications for development and evaluation of new diagnostics and therapeutics
      Jan Terje Andersen (Norway)

Section 3: Biomarkers of Diseases

1. Hotspots sites for glycation of human serum albumin and effect on functional activity and degradation
      Paul Thornalley (United Kingdom)
2. Advanced oxidation protein products: from the oxidant-mediated damage toward the oxidant mediating the disease progression
      Fan Fan Hou (China)
3. The use of ischemia modified albumin (IMA) in clinical practice
      Juan-Carlos Kaski (United Kingdom)

Section 4: Albumin functionalization and clinical applications

1. NO-induced protein Cys modification and its potential clinical application
      Takaaki Akaike (Japan)
2. Albumin-heme complexes: Heme pocket architecture for modulation of oxygen-binding property
      Teruyuki Komatsu (Japan)
3. Albumin dialysis for extracorporeal liver support: basics and clinical results
      Steffen Mitzner (Germany)

【Plenary Lecture】
Albumin as fatty acid transporter
   Ger J van der Vusse (The Netherland)

【Closing Speech】 Ulrich Kragh-Hansen (Denmark)

Symposium 4 (S4)

[Asia Pacific regional ISSX-JSSX joint symposium]
“Pharmacogenomics in Asia - the present & the future; how to translate genomic informations into clinical therapeutics and drug development”
Organizer:
   Ichiro Ieiri (Japan)
   Jin-ding Huang (Taiwan)

【Introduction】 Ichiro Ieiri (Japan)

1. Ethnic difference of drug disposition: contributing factors and perspective.
      Jae-Gook Shin (Korea)
2. Pharmacogenetics in Korea (tentative)
      Jung-Mi Oh (Korea)
3. Pharmacogenetic in China (tentative)
      Honghao Zhou (China)
4. Clinical relevance of NAT2 genotyping in isoniazid dosing
      Li-Jiuan Shen (Taiwan)
5. Pharmacogenomics-guided strategy for eradication of H. pylori (from hospital)
      Takahisa Furuta (Japan)
6. Current status and future perspective in pharmacogenomic biomarkers in clinical trials (from company)
      Imai Yasuhiko (Japan)
7. Pharmacogenetics from regulation (tentative)
      Yoshiaki Uyama (Japan)

【Closing remarks】 Jin-ding Huang (Taiwan)

Forum 2008

	Program Chairman:	Shizuo Narimatsu （Okayama University Graduate School of Biomedical Sciences)
	Perspective on clinical drug-interactions in the 21st century　- preclinical, clinical and regulatory aspects –

Young Scientists' Symposium

	Program Chairman:	Katsuhisa Inoue （Nagoya City University　Graduate School of Pharmaceutial Sciences)
	Future perspectives of drug discovery based on exploratory and innovative technologies

※Please acknowledge that this program is the one as of May, 2008, and some changes will be expected in the future beforehand.